Fig. 1: MYD88 L265P ddPCR assay application in clinical practice. | Leukemia

Fig. 1: MYD88 L265P ddPCR assay application in clinical practice.

From: Guiding clinical management of patients with CNS lymphomas by minimal-invasive detection of ctDNA in cerebrospinal fluid

Fig. 1

A Number of CSF specimens submitted from internal (orange) and external (blue) sites for routine MYD88 L265P testing (grey: total submissions), shown by quarter from quarter 1 in 2022 until quarter 2 in 2024. B Scatter plot depicting submitted CSF volumes from all 205 samples in milliliters (mL). Lines highlight the median and range. C Pie chart showing the distribution of turnaround times in days for MYD88 L265P analyses. D Bar graph depicting the fraction of samples with positive (blue) and negative (gray) CSF-ctDNA results. E Scatter plot highlighting CSF-ctDNA allele frequencies for all CSF analyses. Lines show the median and range. CSF, cerebrospinal fluid; Q, quarter; mL, milliliters; ctDNA, circulating tumor DNA.

Back to article page